Gerald Downey

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Robert H.I. Andtbacka, Frances A. Collichio, Kevin J. Harrington et al. · Journal for ImmunoTherapy of Cancer · 2019 · 438 citations · Full text

Medicine, Immunology, Oncology +17

Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access

Francesca Fumagalli, Valeria Calbi, Maria Grazia Natali Sora et al. · The Lancet · 2022 · 284 citations · Full text

Medicine, Hematology, Immunology +15

Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy

Christine Duncan, Jacob R. Bledsoe, Bartosz Grzywacz et al. · New England Journal of Medicine · 2024 · 122 citations · Full text

Medicine, Hematology, Oncology +16

DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan

Mark Rowland, Gerald Downey, Abdur Rab et al. · Tropical Medicine & International Health · 2004 · 111 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

Kevin J. Harrington, Robert H.I. Andtbacka, Frances A. Collichio et al. · OncoTargets and Therapy · 2016 · 101 citations · Full text

Medicine, Immunology, Oncology +17